MKI67 and neuroendocrine carcinoma: Univariate analysis for PFS showed similar benefit for tumors with Ki-67 ≤ 20% vs > 20% (p 0.001), well-differentiated G1, G2 vs. G3 or NEC (p < 0.001), and surgical vs medical primary management (p 0.031) (Table 2).